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Docetaxel (Taxotere) is a new semisynthetic taxoid that has demonstrated substantial clinical activity against a wide variety of solid tumours (Pazdur et al, 1993; Aamdal et al, 1994; Fossella et al, 1994; Francis et al, 1994a; Francis et al, 1994b; Smyth et al, 1994; Chevallier et al, 1995) . Docetaxel inhibits tubulin depolymerization and promotes microtubule assembly, resulting in dysfunctional microtubules (Pazdur et al, 1993) .
In view of their partly non-overlapping side-effects and their activities in a wide range of tumour types, developing combination chemotherapy regimens, including both taxoids and platins, is of major interest (Rowinsky et al, 1991; Rowinsky et al, 1993; Chaudhry et al, 1994 ). An important dose-dependent side-effect of cisplatin is the development of peripheral neuropathy, mainly affecting thick-fibre-mediated sensory qualities (Thompson et al, 1984; Roelofs et al, 1984; Gerritsen van der Hoop et al, 1990a; Vecht et al, 1991; Hilkens et al, 1994) . Neuropathy has also been reported as a dose-dependent side-effect of treatment with paclitaxel (Taxol) (Lipton et al, 1989; Gerven et al, 1994) . As expected, trials on combination chemotherapy of cisplatin and paclitaxel found a high incidence of peripheral neuropathy (Rowinsky et al, 1991; Rowinsky et al, 1993; Chaudhry et al, 1994) .
Peripheral neurotoxicity has been reported as a frequent, but usually mild side-effect of docetaxel in several phase I and phase II studies (Bissett et al, 1993; Extra et al, 1993; Aamdal et al, 1994; Fossella et al, 1994; Francis et al, 1994a; Francis et al, 1994b; Smyth et al, 1994; Chevallier et al, 1995; Hilkens et al, 1996; New et al, 1996) . The neurotoxic effects of docetaxel in combination chemotherapy with cisplatin are unknown. In our institution, a phase I trial on the combination of docetaxel and cisplatin in metastatic or locally advanced solid tumours was conducted (Pronk et al, 1996) . In order to study the Chemotherapy was administered in 3-weekly regimens. Docetaxel, supplied by Rh8ne-Poulenc Rorer, was given as a 1-h infusion. Cisplatin was dissolved in 3% saline and administered as a 3-h infusion with 24 h hyperhydration. In most patients, pin-prick sensation, Romberg's sign, Romberg's sign with heelto-toe stand and tendon reflexes of the legs were each scored as normal (0) or abnormal (1). A sum-score for these signs and symptoms was calculated (minimum 0, maximum 11). The severity of paraesthesias was graded on a 5-point scale (Table I) . Sensory loss was defined as an abnormal test on either position sense, vibration sense or pin-prick sense. Patients were asked whether they experienced Lhermitte's sign or pain. Distal muscle strength in the lower extremities was tested. Motor signs were defined as the presence of objective weakness. The severity of neuropathy was scored according to the NCI Common Toxicity Criteria (CTC) for sensory neuropathy (Table 1) . VPT was measured at the dorsum of the second metacarpal bone of the left hand with a Vibrameter type IV (Somedic AB, Stockholm, Sweden) and recorded in micrometers (gm) of skin displacement. This vibrameter uses a vibratory frequency of 100 Hz and corrects for pressure-induced alterations of vibratory amplitude. The method of limits was used to obtain the mean VPT, and this was repeated three times (Goldberg et al, 1979) . The VPT has been shown to be a reliable technique to monitor cisplatin neuropathy and shows a good correlation with the sum-score of neuropathic signs and symptoms as observed previously (Elderson et al, 1989 ; Gerritsen van der Hoop et al, 1990b; Hovestadt et al, 1992) . It has also been applied to quantify paclitaxel-induced neuropathy (Gerven et al,1994) . In some patients electrophysiological studies were carried out before and after treatment. Distal latency and nerve conduction velocity (NCV) of the ulnar (sensory and motor), peroneal (motor) and sural nerve, compound motor action potential (CMAP) of the ulnar and peroneal nerve and sensory nerve action potential (SNAP) of ulnar and sural nerve were determined. A 50% decrease in CMAP and SNAP amplitude and a 15% decrease of NCV were considered abnormal.
The first post-treatment evaluation was used as primary end point for the assessment of neurotoxicity. Cycles of docetaxel and cisplatin given after the last neurological evaluation, which occurred in eight patients, were not counted in the analysis and excluded from the calculation of the cumulative dose.
A subdivision was made into three groups, according to cumulative dose of cisplatin and docetaxel. The mean increase in sum-score and the ratio of VPT post-treatment to VPT pretreatment (VPT post-pre ratio) within groups were calculated. A comparison of the severity of neuropathy in relation to cumulative dose was made with two other prospective trials performed in our institution in the same period (Hilkens et al, 1994; Hilkens et al, 1996) . In these trials, cisplatin and docetaxel were studied as single chemotherapeutic agents, and identical methods for measurement of neuropathy were applied as described here. The incidence of neurological signs and symptoms at the first evaluation after the last cycle was determined. Patients with preexisting signs or symptoms were not included in these calculations. Graded paraesthesias pretreatment were included only if there was an increase in the grade of paraesthesias post-treatment. The change in sensory sum-score and the VPT post-pre ratio were calculated for each patient. Spearman rank correlations were calculated to describe the strength of the association between cumulative doses of cisplatin and docetaxel and the increase in sensory sum-score and the VPT post-pre ratio. Because of the skewed distribution of the VPT, the geometric mean was used to determine the mean of the VPT post-pre ratio. For the sensory sum-score, the arithmetic mean was calculated.
RESULTS
Sixty-three patients were entered into the trial. Eight of these 63 patients were excluded for assessment of neurotoxicity because of lack of pretreatment evaluation. Table  2 . Twenty-seven patients had previously been treated with nonneurotoxic chemotherapy. One patient had been treated with vincristine. None of the patients had received prior treatment with cisplatin. Five patients had diabetes mellitus and five patients reported alcohol abuse.
Twenty patients received one to two cycles, six patients three to four cycles, 28 patients five to six cycles and one patient eight cycles before their last evaluation. The mean dose per cycle of cisplatin was 74 mg m-2 (range 50-100 mg m-2) and of docetaxel 82 mg m-2 (range 38-100). The mean given cumulative dose of cisplatin was 297 mg m-2 (range 75-600 mg m-2) and of docetaxel 326 mg m-2 (range 75-600 mg m-2). The mean duration of followup after the last cycle was 96 days (range 7-315 days). Table 3 shows the incidence of neuropathic signs and symptoms at the first post-treatment evaluation. Paraesthesias were seen in 24 patients (44%) in both hands and feet (n=18) or in the feet only (n=6). Three patients suffered from pain in either hands or feet, which was felt to be secondary to the neuropathy. Table 4 shows the mean increase in sensory sum-score, the mean VPT post-pre ratio, the severity of paraesthesias and the CTC-neurosensory grade at first post-treatment evaluation, classified by cumulative dose of docetaxel and cisplatin. According to CTC criteria, 29 patients developed a sensory neuropathy. In the Table 5 Comparison of the severity of neuropathy between patients treated with docetaxel alone (Hilkens et al 1996) and patients treated with docetaxel-cisplatin combination chemotherapy, in relation to the cumulative dose of docetaxel Docetaxel <300 mg m-2 Docetaxel 300-600 mg m-2 aDifference between first post-treatment and pretreatment score. bDifference between first post-treatment and pretreatment score, divided by pretreatment score (pre-post ratio). cincidence at first post-treatment evaluation. In four patients, treatment had to be discontinued because of neurotoxicity. Twenty-three patients had two or more post-treatment evaluations. Two of these patients developed a mild neuropathy (grade 1) during follow-up. In four patients, neuropathy further deteriorated during follow-up; one patient developed a moderate neuropathy (grade 2) and three patients a severe (grade 3) neuropathy.
In 43 patients, the sequence of administration was docetaxel before cisplatin and in 12 patients vice versa. There was no difference in the severity of neurotoxicity as measured with the sensory sum-scores between these two different regimens.
We found a clear correlation between the increase in VPT and the increase in sum-score (rs = 0.34, P = 0.02) following treatment.
Both the cumulative doses of docetaxel and cisplatin showed a statistically significant correlation with the increase in sum-score (rs = 0.44 and 0.39 respectively, P < 0.01) and the change in VPT (rs = 0.68 and 0.65 respectively, P < 0.001). Figure 1 shows the VPT post-pre ratio in relation to cumulative doses of docetaxel and cisplatin. Figure 2 shows the relation of cumulative doses of these drugs and change in sensory sum-score. Electrophysiological studies before and after treatment were carried out in 26 patients. They showed a decrease in SNAP amplitudes in 15 patients, a decrease in CMAP amplitudes in one patient and both a decrease in SNAP and CMAP amplitudes in four patients. The NCV studies were unchanged in six patients, most of whom had been treated with low cumulative doses of both cisplatin and docetaxel. The cumulative dose in the four patients with both motor and sensory involvement was similar to the cumulative dose of patients with only sensory involvement. Table 5 shows a comparison of the severity of neuropathy in relation to cumulative dose of docetaxel between patients in the combination chemotherapy trial and patients treated with docetaxel alone in another prospective trial conducted in our institution (Hilkens et al, 1996) . At low cumulative doses of docetaxel (and consequently also low doses of cisplatin in the combination British Journal of Cancer (1997) 75(3), 417-422 chemotherapy trial), there is a low incidence of neuropathy in both trials. When patients with cumulative doses of docetaxel above 300 mg m-2 are considered, a higher incidence and more severe neuropathy is found in patients treated with combination chemotherapy than in patients treated with docetaxel alone. Figure 3 compares the relative change in VPT and the change in sensory sum-score in relation to the cumulative dose of cisplatin between patients from this trial and patients treated with cisplatin alone (Hilkens et al, 1994) . It shows a more severe neuropathy in the patients treated with the combination chemotherapy regimen, particularly at higher cumulative doses of cisplatin.
DISCUSSION
In recent years, docetaxel has appeared to be one of the most active new antineoplastic agents. Peripheral neuropathy is one of the potentially dose-limiting side-effects. In several phase II trials on docetaxel, a mild to moderate, mainly sensory, neuropathy was observed (Aamdal et al, 1994; Bruntsch et al, 1994; Fossella et al, 1994; Francis et al, 1994 a,b; Smyth et al, 1994; Chevallier et al, 1995; Hilkens et al, 1996; New et al, 1996) . In a study of 41 patients treated with single-agent docetaxel (100 mg m-2 every 3 weeks, cumulative doses 200-1100 mg m-2) 49% of the patients developed a usually mild neuropathy (Hilkens et al, 1996) . The neuropathy appeared to be dose dependent and caused severe and disabling neuropathy in some patients at higher dose levels. Severe motor involvement occurred in two of these patients.
In trials on combination chemotherapy of cisplatin with another taxoid, paclitaxel, a high incidence of neuropathy was found. In a phase I study of paclitaxel (110-200 mg m-2 per cycle) and cisplatin (50-75 mg m-2 per cycle) in 44 patients (median number of cycles, 3; range 1-12), 27% developed a mild to moderate neuropathy (Rowinsky et al, 1991) . The incidence of neuropathy was disproportionately higher than expected with either paclitaxel or cisplatin alone at similar single and cumulative doses. In a study of 32 patients treated with higher doses paclitaxel (135-350 mg m-2 per cycle) and cisplatin (75-100 mg m-2 per cycle), 75% developed a neuropathy (Rowinsky et al, 1993) . It was suggested that the neuropathy was mainly due to paclitaxel. The severity of the neuropathy was related to both the cumulative and single dose of paclitaxel and the presence of a pre-existing medical disorder associated with neuropathy (diabetes, alcoholism). The neuropathy was of axonal nature with predominantly sensory signs, although electrophysiological studies established the additional involvement of motor nerves (Chaudhry et al, 1994) .
To date, there are no results of studies on docetaxel-cisplatin combination chemotherapy regimens. In the present study, we observed that 53% of patients treated with docetaxel and cisplatin, in a wide range of cumulative doses, developed a mainly sensory neuropathy. When only patients with cumulative doses of docetaxel and cisplatin above 200 mg m-2 were considered, 71% developed a neuropathy. At higher dose levels, some patients showed moderate or severe neuropathy. Nine of these patients had motor signs. In 5 out of 26 patients in whom neurophysiological studies were performed, motor involvement was found. Neuropathy was the dose-limiting side-effect in four patients.
We were able to compare the results of this trial with two other trials performed in our institution in which patients were treated with either docetaxel or cisplatin as single agent (Hilkens et al, 1994 (Hilkens et al, , 1996 . As expected, the combination of these two neurotoxic agents tends to induce a more severe neuropathy then either of the two drugs alone. However, as these single and combination chemotherapy schedules were not studied in a comparative trial, this should be interpreted with caution. As the cumulative dose of cisplatin and the cumulative dose of docetaxel were closely related in our study, we could not detect which drug accounted for most of the neuropathy. A synergistic effect of the two drugs cannot be excluded.
The value of the VPT as a sensitive indicator of neuropathy in this study is not unequivocal. Several reports have demonstrated that VPT is a reliable measure of cisplatin neuropathy (Elderson et al, 1989; Gerritsen van der Hoop et al, 1990b; Hovestadt et al, 1992) . In a previous study, we did not establish a significant relationship between VPT and the severity of docetaxel-induced neuropathy, possibly because small fibre functions are compromised in this neuropathy (Hilkens et al, 1996) . The change in VPIT, in this study, can probably be accounted for by cisplatin which mainly affects large myelinated fibres.
In a phase I study on paclitaxel-cisplatin combination chemotherapy, it was suggested that the sequence of cisplatin administration before paclitaxel may be related to more profound neutropenia (Rowinsky et al, 1991) . We were unable to detect differences in the severity of neurotoxicity in relation to the sequence of administration of cisplatin and docetaxel. As only 12 patients received cisplatin before docetaxel, no firm conclusions can be drawn.
In conclusion, the combination chemotherapy of docetaxel and cisplatin induces a dose-dependent sensory neuropathy. At higher dose range, neuropathy is encountered in a relatively high proportion of patients. With cumulative doses of both cisplatin and docetaxel between 200 and 600 mg m-2, one third of the patients developed a moderate or severe neuropathy. The severity of neuropathy is higher than with the use of either cisplatin or docetaxel as a single agent at similar doses. Further study on the possible attenuating effects of neuroprotective agents such as WR-2721 (amifostine) (Mollman et al, 1988; Gandara et al, 1991;  Wadler pt al, 1993), glutathione (Di Re et al, 1993; Cascinu et al, 1995) and nerve growth factor (Apfel et al, 1992; Windebank et al, 1994 ) is warranted.
